Obstructive lung disease treatment developer Nuvaira said today that the FDA has designated its lung denervation system a breakthrough device. The Nuvaira lung denervation system enables a novel bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity, which causes airway hyper-responsiveness or “lung attacks” in both COPD […]
Nuvaira announces Griffin as new CFO
Obstructive lung disease treatment developer Nuvaira announced that Tom Griffin joined the company as its new chief financial officer. Griffin has a 30-year record of leadership roles that included guiding companies through investment financing, commercialization growth and IPO stages, according to a news release. He most recently served as CFO at Avedro, which completed its […]
Nuvaira touts dNerva lung denervation studies
Nuvaira announced multiple peer-reviewed studies that provide further evidence of safety, clinical effectiveness and the mechanisms of targeted lung denervation. The Plymouth, Minn.-based company’s dNerva system is a bronchoscopic procedure designed to disrupt pulmonary nerve input to the lung, reducing the consequences of neural hyperactivity in chronic obstructive pulmonary disease. Nuvaira’s IPS-II trial showed successful […]
Medical Alley companies beat Q1 investment total
A surge in first-quarter 2019 investments in Medical Alley Association member startups pushed them past their performance in the same quarter last year, according to the Minnesota-based trade group. Seven of the 10 largest raises of the quarter went to medical device companies, which propelled the sector to its best first quarter on record, nearly doubling the […]
Nuvaira raises $79m to support COPD device
Respiratory device developer Nuvaira said today that it raised $79 million in a new equity financing round to support its Lung Denervation System. The Lung Denervation System is intended to treat airway hyper-responsiveness, which the Minneapolis-based company said is a pathophysiologic underpinning of both chronic obstructive pulmonary disease and asthma, through a procedure called Targeted […]
5 medtech funding insights you need to know
Venture capital funding isn’t what it used to be for medical device startups, but there are actually reasons to feel optimistic about medtech funding. That was the big takeaway from a four-expert panel at DeviceTalks Minnesota last month. (The next DeviceTalks is Oct. 2 in Boston.) Charlie Whelan, director of transformational health consulting at Frost & Sullivan, […]
